Clinical Trial Update: Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of elotuzumab and lenalidomide after stem cell transplantation in patients with newly diagnosed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Empliciti (elotuzumab)
• Revlimid (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING